Fumikata Hara

Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial

Tsutomu Takashima, Hirofumi Mukai, Fumikata Hara et al. · The Lancet Oncology · 2015 · 93 citations

Metastatic Breast Cancer, Oncology, Breast Oncology +8

The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition

Tomohiko Aihara, Tatsuya Toyama, Masato Takahashi et al. · Breast Cancer · 2016 · 88 citations · Full text

Nursing, Surgical Oncology, Breast Oncology +8

The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells

Hirokuni Ikeda, Naruto Taira, Fumikata Hara et al. · Breast Cancer Research · 2010 · 87 citations · Full text

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients

Norikazu Masuda, Kenichi Inoue, Rikiya Nakamura et al. · International Journal of Clinical Oncology · 2018 · 53 citations · Full text

Breast Oncology, Oncology, Medicine +8

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition

Mitsuo Terada, Aki Ito, Yuichiro Kikawa et al. · Breast Cancer · 2023 · 53 citations · Full text